Ascendis Pharma AS - Asset Resilience Ratio
Ascendis Pharma AS (A71) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Ascendis Pharma AS's Asset Resilience Ratio has changed over time. Check Ascendis Pharma AS (A71) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Ascendis Pharma AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see A71 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Ascendis Pharma AS maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Ascendis Pharma AS Industry Peers by Asset Resilience Ratio
Compare Ascendis Pharma AS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
89bio Inc
NASDAQ:ETNB |
Biotechnology | 71.60% |
|
Jinyu Bio-Technology Co Ltd
SHG:600201 |
Biotechnology | 1.20% |
|
Alpha Tau Medical Ltd
NASDAQ:DRTS |
Biotechnology | 65.79% |
|
Clarity Pharmaceuticals Ltd
AU:CU6 |
Biotechnology | 73.99% |
Annual Asset Resilience Ratio for Ascendis Pharma AS (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Ascendis Pharma AS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€1.18 Billion ≈ $1.38 Billion |
-- |
| 2023-12-31 | 0.88% | €7.28 Million ≈ $8.51 Million |
€825.59 Million ≈ $965.20 Million |
-25.79pp |
| 2022-12-31 | 26.68% | €290.69 Million ≈ $339.84 Million |
€1.09 Billion ≈ $1.27 Billion |
+4.94pp |
| 2021-12-31 | 21.73% | €235.80 Million ≈ $275.67 Million |
€1.08 Billion ≈ $1.27 Billion |
+8.03pp |
| 2020-12-31 | 13.70% | €134.28 Million ≈ $156.99 Million |
€979.79 Million ≈ $1.15 Billion |
-- |
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is a… Read more